KELLI GARRICK: Open Payments
NPI 1215562632 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,865 in 107 payments from 21 companies in 2025. Trend: 2023 $765 · 2024 $1,494 · 2025 $1,865
Food & beverage: $1,865
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $460 |
| PFIZER INC. | 23 | $319 |
| Lilly USA, LLC | 9 | $200 |
| Novo Nordisk Inc | 16 | $178 |
| Axsome Therapeutics, Inc. | 5 | $130 |
| Esperion Therapeutics, Inc. | 5 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $50 |
| Tandem Diabetes Care, Inc. | 2 | $49 |
| Amgen Inc. | 2 | $44 |
Products named: NURTEC ODT, VRAYLAR, UBRELVY, Auvelity, Ozempic, ZEPBOUND, MOUNJARO, NEXLETOL.
Industry payments across AL — which companies pay providers there.
